Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors

Redox Biology

Volumn 6, Issue , 2015, Pages 421-425

  Leon Mateos L ^a   Mosquera, J ^b   Anton Aparicio L ^b  

^a Santiago de Compostela   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Hypertension; Nitric oxide; Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUNITINIB; VASCULOTROPIN; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; CAPILLARY DENSITY; CAPILLARY ENDOTHELIAL CELL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GLOMERULAR INJURY; GLOMERULOPATHY; HUMAN; HYPERTENSION; KIDNEY METASTASIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; PHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; HYPERTENSION; INDOLES; NITRIC OXIDE DONORS; PYRROLES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84941945951     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.09.007     Document Type: Article

References (40)

1. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N. Engl. J. Med. 2007, 356(2):185-187.
2. Roodhart J.M., Langenberg M.H., Witteveen E., Voest E.E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol. 2008, 3(2):132-143.
3. Launay-Vacher V., Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009, 20(1):81-82.
4. Caro J., Morales E., Gutierrez E., Ruilope L.M., Praga M. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J. Clin. Hypertens. (Greenwich) 2013, 15(3):215-216.
5. Tlemsani C., Mir O., Boudou-Rouquette P., Huillard O., Maley K., Ropert S., et al. Posterior reversible encephalopathy syndrome induced by anti-vegf agents. Target Oncol. 2011, 6(4):253-258.
6. Yang R., Thomas G.R., Bunting S., Ko A., Ferrara N., Keyt B., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 1996, 27(6):838-844.
7. Steeghs N., Gelderblom H., Roodt J.O., Christensen O., Rajagopalan P., Hovens M., et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin. Cancer Res. 2008, 14(11):3470-3476.
8. Vázquez S., León L., Fernández O., Lázaro M., Grande E., Aparicio L. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv. Ther. 2012, 29(3):202-217.
9. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356(2):115-124.
10. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27(22):3584-3590.
11. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009, 10(8):757-763.
12. Taraseviciene-Stewart L., Kasahara Y., Alger L., Hirth P., Mc Mahon G., Waltenberger J., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001, 15(2):427-438.
13. Horowitz J.R., Rivard A., van der Zee R., Hariawala M., Sheriff D.D., Esakof D.D., et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 1997, 17(11):2793-2800.
14. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009, 48(1):9-17.
15. Merkus D., Sorop O., Houweling B., Boomsma F., van den Meiracker A.H., Duncker D.J. NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(5):H2075-H2081. Nov.
16. Wiley K.E., Davenport A.P. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br. J. Pharmacol. 2001, 133(4):568-574.
17. Kappers M.H.W., van Esch J.H.M., Sluiter W., Sleijfer S., Danser A.H.J., van den Meiracker A.H. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010, 56(4):675-681.
18. van der Veldt A.A.M., de Boer M.P., Boven E., Eringa E.C., van den Eertwegh A.J.M., van Hinsbergh V.W., et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 2010, 21(4):439-446.
19. Eechoute K., van der Veldt A.A.M., Oosting S., Kappers M.H.W., Wessels J.A.M., Gelderblom H., et al. Polymorphisms in endothelial nitric oxide synthase (enos) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin. Pharmacol. Ther. 2012, 92(4):503-510.
20. Dimmeler S., Assmus B., Hermann C., Haendeler J., Zeiher A.M. Fluid shear stress stimulates phosphorylation of akt in human endothelial cells: involvement in suppression of apoptosis. Circ. Res. 1998, 83(3):334-341.
21. Gurevich F., Perazella M.A. Renal effects of anti-angiogenesis therapy: update for the internist. Am. J. Med. 2009, 122(4):322-328.
22. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W., Edwards H.V., Watt G.C. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J. Clin. Invest. 1997, 99(8):1873-1879.
23. Matsuura A., Yamochi W., Hirata K., Kawashima S., Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998, 32(1):89-95.
24. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003, 111(5):707-716.
25. Moncada S., Palmer R.M., Higgs E.A. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988, 12(4):365-372.
26. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329(27):2002-2012.
27. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995, 9(13):1319-1330.
28. Benjamin N., O'Driscoll F., Dougall H., Duncan C., Smith L., Golden M., McKenzie H. Stomach NO synthesis. Nature 1994, 368(6471):502. Apr 7.
29. Bryan N.S., Fernandez B.O., Bauer S.M., Garcia-Saura M.F., Milsom A.B., Rassaf T., et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat. Chem. Biol. 2005, 1(5):290-297.
30. Kibbe M.R., Li J., Nie S., Watkins S.C., Lizonova A., Kovesdi I., et al. Inducible nitric oxide synthase (inos) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J. Vasc. Surg. 2000, 31(6):1214-1228.
31. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
32. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376(6535):66-70.
33. Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009, 54(3):652-658.
34. Bilbao-Meseguer I., Jose B.S., Lopez-Gimenez L.R., Gil M.A., Serrano L., Castaño M., et al. Drug interactions with sunitinib. J. Oncol. Pharm. Pract. 2015, 21(1):52-66.
35. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). J. Hypertens. 2007 2007, 25(6):1105-1187.
36. de Jesus-Gonzalez N., Robinson E., Moslehi J., Humphreys B.D. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012, 60(3):607-615.
37. Grünwald V., Kalanovic D., Merseburger A.S. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J. Urol. 2010, 28(3):343-351.
38. Aparicio-Gallego G., Afonso-Afonso J., León-Mateos L., Fírvida-Pérez J., Vázquez-Estévez S., Lázaro-Quintela M. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011, 22(1):1-8.
39. Kruzliak P., Kovacova G., Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis 2013, 16(2):289-295.
40. Kruzliak P., Novák J., Novák M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am. J. Hypertens. 2014, 27(1):3-13.